Sanctura XR Could Quench Indevus’ Thirst For Once-Daily Incontinence Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from the first of two Phase III trials of trospium extended-release report 8.7% incidence of dry mouth, compared to 20.1% for twice-daily Sanctura.
You may also be interested in...
Indevus Gains Sanctura XR Approval
The molecule’s “highly differentiated profile” will set it apart from others in the crowded urinary incontinence space, Indevus tells “The Pink Sheet” DAILY.
Indevus Gains Sanctura XR Approval
The molecule’s “highly differentiated profile” will set it apart from others in the crowded urinary incontinence space, Indevus tells “The Pink Sheet” DAILY.
Sanctura XR NDA Filing On Target For Year-End
Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.